CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF

Tech ID: 30175 / UC Case 2019-102-0

Patent Status

Country Type Number Dated Case
United Kingdom Issued Patent 2595606 09/21/2022 2019-102
United States Of America Issued Patent 11,377,646 07/05/2022 2019-102
Germany Issued Patent 21 2020 000 516.8 01/17/2022 2019-102
Japan Published Application 2022-521771 04/12/2022 2019-102
European Patent Office Published Application 3935156 A0 01/12/2022 2019-102
Mexico Published Application MX/A/2021/01055 01/12/2022 2019-102
United States Of America Published Application 20210403888 12/30/2021 2019-102
China Published Application CN113811607A 12/17/2021 2019-102
United States Of America Published Application 20210324356 10/21/2021 2019-102
United States Of America Published Application 20210324358 10/21/2021 2019-102
United States Of America Published Application 20210317447 10/14/2021 2019-102
United States Of America Published Application 20210301271 09/30/2021 2019-102
United States Of America Published Application 20210254038 08/19/2021 2019-102
United States Of America Published Application 20210238567 08/05/2021 2019-102
Australia Published Application 2019-102
Canada Published Application 2019-102
Hong Kong Published Application 40064319 A 2019-102
Patent Cooperation Treaty Published Application WO2020181101 09/10/2020 2019-102
 

Additional Patent Pending

Brief Description


The CRISPR-Cas system is now understood to confer bacteria and archaea with acquired immunity against phage and viruses. CRISPR-Cas systems consist of Cas proteins, which are involved in acquisition, targeting and cleavage of foreign DNA or RNA, and a CRISPR array, which includes direct repeats flanking short spacer sequences that guide Cas proteins to their targets.  Class 2 CRISPR-Cas are streamlined versions in which a single Cas protein bound to RNA is responsible for binding to and cleavage of a targeted sequence. The programmable nature of these minimal systems has facilitated their use as a versatile technology that is revolutionizing the field of genome manipulation.  Current CRISPR Cas technologies are based on systems from cultured bacteria, leaving untapped the vast majority of organisms that have not been isolated.  There is a need in the art for additional Class 2 CRISPR/Cas systems (e.g., Cas protein plus guide RNA combinations).

 

 

UC Berkeley researchers discovered a new type of Cas 12 protein.  Site-specific binding and/or cleavage of a target nucleic acid (e.g., genomic DNA, ds DNA, RNA, etc.) can occur at locations (e.g., target sequence of a target locus) determined by base-pairing complementarity between the Cas12 guide RNA (the guide sequence of the Cas12 guide RNA) and the target nucleic acid.  Similar to CRISPR Cas9, Cas12 enzymes are expected to have a wide variety of applications in genome editing and nucleic acid manipulation.  

 


Suggested uses


  • Genome editing
  • Gene therapy
  • Diagnostic assays
  • Research tools

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Doudna, Jennifer A.

Other Information

Keywords

CRISPR, Cas 12, Cas12J

Categorized As

Additional Technologies by these Inventors